{"id":"ceftazidime-avibactam-aztreonam","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that binds penicillin-binding proteins and inhibits bacterial cell wall cross-linking. Avibactam is a β-lactamase inhibitor that protects ceftazidime from enzymatic degradation by resistant organisms. Aztreonam is a monobactam antibiotic that also inhibits cell wall synthesis and provides synergistic coverage, particularly against multidrug-resistant gram-negative pathogens including Pseudomonas aeruginosa and Enterobacteriaceae.","oneSentence":"Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against β-lactamase degradation, and aztreonam provides additional coverage against gram-negative bacteria including those resistant to other β-lactams.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:51.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Complicated urinary tract infections"},{"name":"Hospital-acquired and ventilator-associated bacterial pneumonia"},{"name":"Multidrug-resistant gram-negative bacterial infections"}]},"trialDetails":[{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06419296","phase":"","title":"Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.","status":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2024-06-01","conditions":"Bacteremia","enrollment":265},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":29},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT03978091","phase":"PHASE1, PHASE2","title":"A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-09","conditions":"Bacterial Infection","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftazidime-avibactam + Aztreonam","genericName":"Ceftazidime-avibactam + Aztreonam","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against β-lactamase degradation, and aztreonam provides additional coverage against gram-negative bacteria including those resistant to other β-lactams. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired and ventilator-associated bacterial pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}